Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Cancer Gene Ther. 2012 Jan 13;19(4):282–291. doi: 10.1038/cgt.2011.90

Fig. 5.

Fig. 5

Number of IFNγ secreting CD4 T-cells harvested from lymph nodes in animals receiving various treatments. Means of 3 experiments with standard error bars.

A. Implanted with D2F2/E2. Treated with rrVSV and anti-CTLA4 MAb. Challenged >100 days later with D2F2/E2 (erbb2 expressing).

B. Implanted with D2F2/E2. Treated with rrVSV and anti-CTLA4 MAb. Challenged >100 days later with D2F2 (non-erbb2 expressing).

C. No tumor implanted. Treated with rrVSV and anti-CTLA4 MAb. Challenged >60-100 days later with D2F2/E2 (erbb2 expressing).

D. No tumor. No treatment. Challenged with D2F2/E2 (erbb2 expressing).